Navigation Links
Oral Topical Formulation, ARMS-I, Provides Protection Against Upper Respiratory Infections as well as Reducing Severity and Duration of Cold
Date:2/7/2017

CLEVELAND, Feb. 7, 2017 /PRNewswire/ -- The findings of a randomized proof-of-concept clinical trial demonstrating that the oral spray formulation, ARMS-I, provided protection against upper respiratory tract infections ("URIs") in the enrolled study participants, while reducing the severity and duration of cough and sore throat have just been released.

Funded by ARMS Pharmaceutical, the double-blinded, placebo-controlled trial was conducted by University Hospital's Cleveland Medical Center's Division of Infectious Diseases and Case Western Reserve University. The conclusion of the study states, "ARMS-I is safe and well-tolerated, and it reduces influenza symptoms. This product has the potential to prevent viral upper respiratory tract infections."

Chief Scientific Officer of ARMS Pharmaceutical, Dr. Mahmoud Ghannoum said, "The results confirm that our ARMS-I technology has tremendous potential to lead the next generation of drugs in not only the prevention of many upper respiratory infectious diseases, such as influenza, rhinovirus and respiratory syncytial virus, but in the treatment of them as well." 

ARMS-I is a patented formulation, comprising a broad-spectrum antimicrobial agent (cetylpyridinium chloride, "CPC") and components (glycerin and xanthan gum) that form a barrier on the host mucosa, thus preventing viral contact with the host cells and invasion. 

The U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for a pharmacokinetic trial of its ARMS-I drug, as the company continues to study and develop the use of ARMS-I for its first indication as a potential drug for the prevention of influenza.

"It is an exciting time for the company as we actively begin discussions with potential strategic partners to bring ARMS-I to market, a drug with the potential to help millions of people prevent influenza without the worries of side effects or viral resistance," added Afif Ghannoum, Chief Executive Officer of ARMS Pharmaceutical.

About ARMS Pharmaceutical LLC
ARMS Pharmaceutical LLC, a clinical stage pharmaceutical company, was founded in 2013. The company focuses on the R&D of its ARMS technology platform. ARMS-I is the company's lead drug candidate for the prevention of influenza. Through strategic partnerships, ARMS Pharmaceutical plans to commercialize its ARMS platform for the prevention and treatment of various infectious diseases.

Media Contact:
BLAZE PR / Matt Kovacs
mkovacs@blazepr.com
310-395-5050

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oral-topical-formulation-arms-i-provides-protection-against-upper-respiratory-infections-as-well-as-reducing-severity-and-duration-of-cold-300402975.html


'/>"/>
SOURCE ARMS Pharmaceutical LLC
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
2. Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetriks
3. Encore Vision, Inc. Announces Completion of Target Enrollment in Clinical Study Evaluating Topical EV06 for the Treatment of Presbyopia
4. Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
5. Snapshot of Innovations in R&D Targeting Key Applications of Drug Delivery Technologies - Oral Route, Pulmonary, Topical, Implantable, Injectable, Transdermal & Transmucosal Route Analysis
6. Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology
7. Teligent, Inc. Announces Submission of Two Topical ANDAs
8. Global Topical Drug Delivery Partnering 2010-2015
9. Study Shows Safety of BioPharmX Topical Formulation
10. Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
11. Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/8/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed ... a health care service center company based in ... in relationship management programs for leading pharmaceutical manufacturers and ... WRB will join Envoy Health Management, LLC ... manufacturers, biotech firms, and other service companies. Together, WRB ...
(Date:5/4/2017)... -- Fortuna Fix Inc. (" Fortuna "), a private, clinical-stage ... the need for embryonic and fetal stem cells by using ... Fortuna announced today the launch of its ... MD, PhD; Father Kevin FitzGerald , S.J., PhD; Col. ... James Giordano , PhD. "We are excited and ...
Breaking Medicine Technology:
(Date:5/27/2017)... (PRWEB) , ... May 27, 2017 , ... In any ... Regardless of the talent of your dental team at presenting treatment, there will always ... invest a lot of time and money on best practices when it comes to ...
(Date:5/26/2017)... ... , ... Mediaplanet is proud to announce the launch of its newest edition ... readers on how to take care of all aspects of their skin. , On ... Dancing with the Stars professional, Witney Carson, shares her journey with the disease that ...
(Date:5/26/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) ... legislative activity and the latest regulatory concerns impacting RBMA members. The Legislative Education ... will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner in Mclean, ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the ... narrowly passed the U.S. House on May 4, would result in 23 million Americans ... continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , ...
Breaking Medicine News(10 mins):